Sigma Investment Counselors’s Teva Pharmaceuticals TEVA Stock Holding History

Sigma Investment Counselors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5,848	Closed	-$212K	–	140
2016 Q4	$212K	Hold	5,848	–	–	0.03%	120
2016 Q3	$269K	Hold	5,848	–	–	0.04%	107
2016 Q2	$294K	Hold	5,848	–	–	0.05%	103
2016 Q1	$313K	Sell	5,848 -550	-9%	-$32.3K	0.06%	100
2015 Q4	$420K	Buy	6,398 +450	+8%	+$27.8K	0.08%	87
2015 Q3	$336K	Hold	5,948	–	–	0.07%	90
2015 Q2	$352K	Buy	5,948 +100	+2%	+$6.17K	0.07%	90
2015 Q1	$364K	Hold	5,848	–	–	0.07%	90
2014 Q4	$336K	Sell	5,848 -200	-3%	-$11.1K	0.06%	98
2014 Q3	$325K	Sell	6,048 -300	-5%	-$15.9K	0.06%	98
2014 Q2	$333K	Hold	6,348	–	–	0.07%	92
2014 Q1	$335K	Hold	6,348	–	–	0.07%	89
2013 Q4	$254K	Hold	6,348	–	–	0.05%	96
2013 Q3	$240K	Sell	6,348 -600	-9%	-$23.4K	0.06%	99
2013 Q2	$272K	Buy	+6,948	New	+$271K	0.07%	88

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sigma Investment Counselors's TEVA Position: Q1 2017 in Review

Sigma Investment Counselors sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 5,848 shares — an estimated $212K sold.

Sigma Investment Counselors first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $420K in Q4 2015. 687 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Sigma Investment Counselors reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Sigma Investment Counselors sold 5,848 Teva Pharmaceuticals shares in Q1 2017, an estimated $212K.
Sigma Investment Counselors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Sigma Investment Counselors's Teva Pharmaceuticals position peaked at $420K in Q4 2015.
687 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Sigma Investment Counselors's 13F filing for Q1 2017, filed 8 May 2017.